



Adult CIRB - Late Phase Emphasis Meeting Agenda

April 16, 2026

I New Study - Initial Review

A072402, Mycophenolate Mofetil to Overcome Glioblastoma Resistance to Radiotherapy and Temozolomide (Version Date 03/16/26)

II New Study - Initial Review

AMC-119, Epcoritamab in Combination with Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL) (BEDROCK Study) (Version Date 03/04/26)

III Amendment

AMC-112, Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma (Version Date 02/27/26)

IV Amendment Prior to Activation

MM3TCT-A03, A Two Cohort, Randomized, Open-Label, Phase II Signal-Finding Study of Venetoclax Combined with Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Complete Remission: A MyeloMATCH Sub-Study (Version Date 02/18/26)

V Continuing Review

A032303, GAIN-BCG: Gemcitabine Alternating with INtravesical BCG Randomized Against BCG Alone for Patients with Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Version Date 06/03/25)

VI Continuing Review

A092104, A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy (Version Date 11/11/25)

VII Continuing Review

A092105, Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma that have Progressed after Platinum Treatment and Immunotherapy (Version Date 07/29/25)

VIII Continuing Review

EA8212, A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) (Version Date 08/13/25)

IX Continuing Review

NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (Version Date 09/02/25)

X Continuing Review

NRG-GU013, The Phase III "High Five Trial" Five Fraction Radiation for High-Risk Prostate Cancer (Version Date 12/10/25)



XI Continuing Review

S2209, A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance (Version Date 01/16/26)
